Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
346.07
-3.39 (-0.97%)
Jul 9, 2025, 10:09 AM - Market open
Elevance Health Stock Forecast
Stock Price Forecast
The 14 analysts that cover Elevance Health stock have a consensus rating of "Strong Buy" and an average price target of $512.36, which forecasts a 48.05% increase in the stock price over the next year. The lowest target is $465 and the highest is $615.
Price Target: $512.36 (+48.05%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 9, 2025.
Analyst Ratings
The average analyst rating for Elevance Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 9 | 9 | 8 | 8 | 7 | 7 |
| Hold | 2 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $510 → $500 | Strong Buy | Maintains | $510 → $500 | +44.48% | Jun 9, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $478 | Buy | Reiterates | $478 | +38.12% | Jun 4, 2025 |
| Barclays | Barclays | Buy Maintains $522 → $480 | Buy | Maintains | $522 → $480 | +38.70% | Jun 2, 2025 |
| Argus Research | Argus Research | Strong Buy Maintains $450 → $465 | Strong Buy | Maintains | $450 → $465 | +34.37% | Apr 25, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $478 | Buy | Reiterates | $478 | +38.12% | Apr 23, 2025 |
Financial Forecast
Revenue This Year
196.60B
from 176.81B
Increased by 11.19%
Revenue Next Year
210.93B
from 196.60B
Increased by 7.29%
EPS This Year
34.75
from 25.68
Increased by 35.31%
EPS Next Year
39.69
from 34.75
Increased by 14.22%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 208.8B | 223.1B | 244.8B | ||
| Avg | 196.6B | 210.9B | 228.3B | ||
| Low | 189.1B | 201.8B | 213.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.1% | 13.5% | 16.1% | ||
| Avg | 11.2% | 7.3% | 8.2% | ||
| Low | 6.9% | 2.6% | 1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.33 | 43.68 | 50.74 | ||
| Avg | 34.75 | 39.69 | 45.84 | ||
| Low | 33.09 | 37.61 | 42.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.5% | 25.7% | 27.8% | ||
| Avg | 35.3% | 14.2% | 15.5% | ||
| Low | 28.9% | 8.2% | 6.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.